Answers are grounded in this paper and cite their sources.
Correspondence reveals poorer quality of life in viral hepatitis with MASLD, highlighting the need for refined clinical management.
To the Editor, We read with great interest the study by Papatheodoridis et al., which used a large multinational registry and validated patientreported outcome (PRO) instruments to characterize chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection with and without superimposed metabolic dysfunctionassociated steatotic liver disease (MASLD) [1].The finding that almost half of participants met the study definition of MASLD, and that these participants reported poorer disease-specific health-related quality of life, draws welcome attention to metabolic health in viral hepatitis.Several issues may help refine the interpretation and clinical application of these findings.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: